A protein called YAP, which drives the growth of organs during development and regulates their size in adulthood, plays a key role in the emergence of resistance to targeted cancer therapies, according to a new study led by UC San Francisco researchers.
MRV Research
Ipilimumab plus fotemustine demonstrated long-term efficacy in metastatic melanoma
The combination of ipilimumab and fotemustine demonstrated long-term efficacy in patients with metastatic melanoma, according to extended follow-up results of a phase 2 study.
Prognostic Differences Between Male and Female Melanoma Patients
In a recent study titled “Prognostic differences across sexes in melanoma patients: what has changed from the past?”, published in Melanoma Research, a research team from the University of Turin has designed a single-institution hospital-based cohort study to evaluate the different trends across time in male versus female melanoma patients.
Melanoma Pigmentation Linked to Mitochondrial ROS Levels
A new study from The Medical School of Newcastle University is assigning guilt by association to mitochondrial function and melanoma. Melanoma skin cancer cells that display high levels of pigmentation also generate a high level of reactive oxygen species (ROS) in their mitochondria, suggesting new drug targets for treatment.